Fenofibrate

證據等級: L5

預測適應症: 10 個

Fenofibrate: From Dyslipidaemia to Homozygous Familial Hypercholesterolemia

One-Sentence Summary

Fenofibrate is a fibrate-class lipid-regulating agent conventionally used for dyslipidaemia and hypertriglyceridaemia. The TxGNN model predicts it may be effective for Homozygous Familial Hypercholesterolemia (HoFH), but this direction is currently supported by only 1 clinical trial (not involving fenofibrate itself) and 11 publications, most of which are historical case-level data.

Quick Overview

Item	Content
Original Indication	Not specified in this data source (no TGA/ARTG licence records available). Fenofibrate is generically known as a fibrate-class agent for dyslipidaemia/mixed hyperlipidaemia.
Predicted New Indication	Homozygous Familial Hypercholesterolemia (HoFH)
TxGNN Prediction Score	99.91%
Evidence Level	L4
Australia Market Status	Not Marketed
Number of ARTG Entries	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on known information, fenofibrate is a peroxisome proliferator-activated receptor alpha (PPARα) agonist belonging to the fibrate class, which lowers triglycerides and modestly raises HDL cholesterol, and has historically been used in dyslipidaemia and mixed hyperlipidaemia.

HoFH, however, results from near-complete loss of LDL-receptor function and typically requires aggressive LDL-lowering strategies — high-intensity statins, PCSK9 inhibitors, or LDL apheresis. Fenofibrate does not correct the LDL-receptor defect and has no established role as a primary HoFH therapy; the drug-disease link identified by TxGNN appears to be driven mainly by shared lipid-disorder terminology rather than a validated pharmacological mechanism.

The only supporting clinical evidence is limited to small, decades-old case series (e.g. a 1984 cohort in which one HoFH patient showed the largest cholesterol reduction among a broader type II hyperlipoproteinaemia population) — not a dedicated HoFH trial. This is consistent with the low evidence level (L4) and “Hold” recommendation assigned to this candidate.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrolment	Key Findings
NCT03510715	Phase 3	Completed	18	Evaluated alirocumab (a PCSK9 inhibitor, not fenofibrate) in children/adolescents with HoFH on background therapy; assessed LDL-C reduction at 12–48 weeks. Included here only for disease overlap — no fenofibrate arm.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
6593751	1984	Cohort	Pharmacological Research Communications	22 type II hyperlipoproteinaemia patients on fenofibrate 300 mg/day; one HoFH patient showed the largest total/LDL-cholesterol reduction in the cohort.
2042836	1991	Review	Annals of the New York Academy of Sciences	Reviews pharmacologic/surgical treatment of dyslipidaemic children, noting fenofibrate among agents used in familial hypercholesterolaemia.
24734312	2014	PK study	Pharmacotherapy	Characterises pharmacokinetic interactions between lomitapide (an approved HoFH adjunct) and lipid-lowering agents including fenofibrate.
37979722	2024	Review	Indian Heart Journal	Notes fenofibrate’s most definite indication is fasting triglyceride >500 mg/dL to reduce pancreatitis risk, not LDL-driven disease like HoFH.
24946816	2014	Review	Internal Medicine Journal	Discusses liver transplantation for HoFH in an era of emerging lipid-lowering therapies (contextual, not fenofibrate-specific).
28437620	2017	Guideline	Endocrine Practice	AACE/ACE dyslipidaemia management and cardiovascular prevention guideline (general context).
26432726	2015	Review	Indian Heart Journal	Reviews LDL-C reduction strategies including statins and PCSK9 inhibitors for severe hypercholesterolaemia.
9129869	1997	Review	Drugs	Pharmacology and therapeutic potential of atorvastatin in hyperlipidaemia (comparator class, not fenofibrate).
9627539	1998	Review	The Canadian Journal of Cardiology	Advances in dyslipidaemia drug treatment focused on atorvastatin.
35499807	2022	Review	Current Atherosclerosis Reports	Reviews dyslipidaemia management in pregnancy (general context, not HoFH-specific).

Australia Market Information

No ARTG entries were found for Fenofibrate in this data source (0 of 0 licences on record).

Safety Considerations

Please refer to the TGA-approved Product Information (PI) for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: Fenofibrate has no established mechanistic link to the LDL-receptor defect underlying HoFH, and the supporting evidence is a single unrelated (non-fenofibrate) trial plus mostly indirect, decades-old literature — evidence level L4 is insufficient to advance this candidate.

To proceed, the following is needed:

Fenofibrate mechanism of action (MOA) data from DrugBank (currently marked as a data gap, high impact on mechanistic assessment)
TGA-approved Product Information — warnings, contraindications and drug interactions (currently marked as a blocking data gap for safety screening)
Confirmation of Australian market/ARTG status, since 0 licences is unusual for a long-marketed generic and should be verified against the TGA database directly
A dedicated fenofibrate-in-HoFH trial or registry data, rather than reliance on historical case-level cohorts

Note: Among the other TxGNN-predicted indications in this evidence pack, hyperlipoproteinemia (rank 2, score 99.65%) has substantially stronger evidence — 34 clinical trials (several graded A, directly testing fenofibrate) and evidence level L1 — with a “Proceed with Guardrails” recommendation. This may be a more promising candidate for near-term evaluation than HoFH.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.